BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Spinal Muscular Atrophy readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Spinal Muscular Atrop
 hy\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05067790-10799@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Spinraza (Nusinersen): Phase 3 readout est. (NCT05067790)
DESCRIPTION:Spinraza (Nusinersen)\, phase 3\, Spinal Muscular Atrophy.\nStu
 dy: A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB0
 58) Given as Injections to Participants With Spinal Muscular Atrophy (SMA)
  Who Were Previously Treated With Risdiplam (ASCEND)\nEstimated primary co
 mpletion: 24 September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nusinersen#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05067790
URL:https://assetmemo.bio/drug/nusinersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444476-10997@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20280623
DTEND;VALUE=DATE:20280624
SUMMARY:Risdiplam (Evrysdi): Phase 3 readout est. (NCT07444476)
DESCRIPTION:Risdiplam (Evrysdi)\, phase 3\, Spinal Muscular Atrophy.\nStudy
 : A Study to Learn About Salanersen's (BIIB115) Effects on Movement and It
 s Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy 
 (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With 
 Risdiplam\nEstimated primary completion: 23 June 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/risdiplam-evrysdi#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07444476
URL:https://assetmemo.bio/drug/risdiplam-evrysdi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047144-208@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Isembyld (apitegromab): Phase 2 readout est. (NCT07047144)
DESCRIPTION:Isembyld (apitegromab)\, phase 2\, Spinal Muscular Atrophy.\nSt
 udy: A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Th
 an 2 Years Old and Have Spinal Muscular Atrophy\nEstimated primary complet
 ion: November 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 pitegromab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07047144
URL:https://assetmemo.bio/drug/apitegromab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047144-10799@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Spinraza (Nusinersen): Phase 2 readout est. (NCT07047144)
DESCRIPTION:Spinraza (Nusinersen)\, phase 2\, Spinal Muscular Atrophy.\nStu
 dy: A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Tha
 n 2 Years Old and Have Spinal Muscular Atrophy\nEstimated primary completi
 on: November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nu
 sinersen#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07047144
URL:https://assetmemo.bio/drug/nusinersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047144-10997@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Risdiplam (Evrysdi): Phase 2 readout est. (NCT07047144)
DESCRIPTION:Risdiplam (Evrysdi)\, phase 2\, Spinal Muscular Atrophy.\nStudy
 : A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 
 2 Years Old and Have Spinal Muscular Atrophy\nEstimated primary completion
 : November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/risd
 iplam-evrysdi#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07047144
URL:https://assetmemo.bio/drug/risdiplam-evrysdi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07846696-10799@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Spinraza (Nusinersen): Phase 3 readout est. (NCT07846696)
DESCRIPTION:Spinraza (Nusinersen)\, phase 3\, Spinal Muscular Atrophy.\nStu
 dy: An Open Label Individual Patient (OLIP)-02 Study of Nusinersen (BIIB05
 8)\nEstimated primary completion: 31 December 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/nusinersen#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07846696
URL:https://assetmemo.bio/drug/nusinersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
